The company said consolidated gross margin for the 3 and 6 months ended April 30, 2025 increased to 68% from 67% in the prior-year period, citing efficiency gains and a more favorable product and regional mix.

10-QQuarterly reportFiled May 30, 2025Period of report Apr 30, 2025Summary published (UTC) Oct 11, 2026

Key points

AI summary

The company said consolidated gross margin for the 3 and 6 months ended April 30, 2025 increased to 68% from 67% in the prior-year period, citing efficiency gains and a more favorable product and regional mix.
The company said CooperVision net sales grew across all categories but were partially offset by unfavorable foreign exchange rate fluctuations of approximately $7.7 million and $22.4 million for the 3 and 6 months, respectively. Toric and multifocal grew primarily through the success of Biofinity and MyDay.
The company cited increased sales of Paragard contraceptive intrauterine devices and the acquisition of obp Surgical on August 1, 2024 as drivers of CooperSurgical office and surgical net sales growth for the 3 months. It said operating income for the 6 months decreased due to an increase in amortization expense.
The company said working capital as of April 30, 2025 was $1,113.2 million. It repurchased 0.5 million shares of common stock for $40.6 million during the 3 and 6 months, with $215.8 million remaining authorized for repurchase.

Key figures

Quarter ended April 30, 2025

Revenue: $1.0B
Operating income: $185M
Net income: $88M
EPS: $0.44
Gross profit: $679M

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Gross Margin 68% and Foreign Exchange Impact

The company said consolidated gross margin for the 3 and 6 months ended April 30, 2025 increased to 68% from 67% in the prior-year period, citing efficiency gains and a more favorable product and regional mix.

Source · Based on the MD&A text of the filing

CooperVision Net Sales and Foreign Exchange Impact

The company said CooperVision net sales grew across all categories but were partially offset by unfavorable foreign exchange rate fluctuations of approximately $7.7 million and $22.4 million for the 3 and 6 months, respectively. Toric and multifocal grew primarily through the success of Biofinity and MyDay.

Source · Based on the MD&A text of the filing

CooperSurgical Sales and Operating Income

The company cited increased sales of Paragard contraceptive intrauterine devices and the acquisition of obp Surgical on August 1, 2024 as drivers of CooperSurgical office and surgical net sales growth for the 3 months. It said operating income for the 6 months decreased due to an increase in amortization expense.

Source · Based on the MD&A text of the filing

Liquidity and Share Repurchases

The company said working capital as of April 30, 2025 was $1,113.2 million. It repurchased 0.5 million shares of common stock for $40.6 million during the 3 and 6 months, with $215.8 million remaining authorized for repurchase.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.